|Bid||0.7518 x 800|
|Ask||0.7550 x 900|
|Day's Range||0.7195 - 0.8000|
|52 Week Range||0.7195 - 4.0500|
|Beta (3Y Monthly)||-0.36|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 7, 2018 - Nov 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.13|
NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
NantHealth, Inc. (NH) delivered earnings and revenue surprises of 23.08% and -10.83%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
CULVER CITY, Calif.-- -- Total Revenue in Q3 was $22.3 Million SaaS revenue of $15.9 million in Q3, up 5% from $15.2 million in prior year Q3 Enhanced efficiencies continued to drive reduced operating expenses and improved adjusted bottom line results Sequencing and Molecular Analysis, 930 total tests ordered in Q3, including 461 GPS Cancer® and 469 Liquid GPS® Tests; continued sequential quarterly ...
NantHealth demonstrates new DeviceConX™ features including enterprise support for larger health systems and high fidelity waveform capture
New DeviceConX Enhancements Showcased at the Healthcare Information and Management Systems Society Interoperability Showcase™ Asia Pacific Conference and Exhibition Featuring NantHealth, B.
--Slight Delay in Reporting Financial Results, Due to Effects of Hurricane Michael--
NantHealth’s Liquid GPS™ technology shows promise in the monitoring of key biomarkers in metastatic colorectal cancer
NEW YORK, Oct. 19, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Two important questions to ask before you buy NantHealth Inc (NASDAQ:NH) is, how it makes money and how it spends its cash. After investment, what’s left over is what belongs Read More...
NantHealth Inc (NASDAQ:NH), a US$213.3m small-cap, is a healthcare company operating in an industry, which has experienced tailwinds from issues such as higher demand driven by an aging population andRead More...
Nikko Khazana and Mark Mozley will help drive growth of NantHealth’s portfolio, including GPS Cancer® and Liquid GPS products
New, peer-reviewed research utilizing NantOmics technology, which powers NantHealth’s (NH) GPS Cancer ® is giving scientists fresh insights into the driving mechanisms behind a form of rare skin cancer as well as therapies to treat patients. Scientists from NantOmics as well as the University of California San Francisco and Thomas Jefferson University in Philadelphia published that chronic inflammation caused by a rare, inherited childhood skin disorder known as recessive dystrophic epidermolysis bullosa (RDEB) can lead to cancer.
NantHealth, Inc. (NH) delivered earnings and revenue surprises of -11.11% and -10.01%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
CULVER CITY, Calif.-- -- Liquid GPS® Successfully Launched in Q2 Total Revenue in Q2 was $22.0 Million Revenue in 2017 Q2 included a large completed Connected Care device implementation of approximately $4 million, benefiting prior period revenue of $23.5 million SaaS revenue of $16.2 million in Q2, up 9% from $14.9 million in prior year Q2 In June 2018, introduced two SaaS products on the NaviNet ...
NEW YORK, NY / ACCESSWIRE / August 9, 2018 / NantHealth, Inc. (NASDAQ: NH ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 9, 2018 at 4:30 PM Eastern Time. To ...
NantHealth, Inc. , a next-generation, evidence-based, personalized healthcare company, today announced that it will report financial results for its 2018 second quarter on Thursday, August 9, 2018, after market close.
NEW YORK , July 31, 2018 /PRNewswire/ -- Hynes Keller & Hernandez, LLC is investigating potential claims against the Board of Directors of NantHealth, Inc. (NASDAQ: NH) concerning possible breaches of ...
NantHealth Inc’s (NASDAQ:NH): NantHealth, Inc., together with its subsidiaries, operates as an evidence-based personalized healthcare company in the United States and internationally. The US$358.34m market-cap posted a loss in itsRead More...
NantHealth, Inc. announced two exciting new product launches - Provider Initiated Document Exchange and Authorization Appeals - on the nation’s leading payer-provider collaboration platform, NaviNet® Open, at the 2018 AHIP Institute and Expo.
NantHealth , a next-generation healthcare company, will exhibit and present at America’s Health Insurance Plans Institute & Expo 2018 taking place June 20-22, 2018 at the San Diego Convention Center in San Diego, CA at booth #824.